RNA interference (RNAi) can be used to inhibit viral replication in mammalian cells and therefore could be a powerful new antiviral therapy. Small interfering RNA (siRNA) may be effective for RNAi, but there are some technical problems that must be solved in each case, for example, predicting the effective siRNA target site and targeting heterogeneous sequences in a virus population. We show here that diced siRNA generated from long doublestranded RNA (dsRNA) is highly effective for inducing RNAi in HuH-7 cells harboring hepatitis C virus (HCV) replicons and can overcome variations in the HCV genotype. However, in mammalian cells, long dsRNA induced an interferon response and caused cell death. Here we describe an improvement of this method, U6 promoter-driven expression of long hairpin-RNA with multiple point mutations in the sense strand. This can efficiently silence HCV RNA replication and HCV protein expression without triggering the interferon response or cell death normally caused by dsRNA. In conclusion, intracellular-diced dsRNA efficiently induces RNAi, and, despite the high rate of mutation in HCV, it should be a feasible therapeutic strategy for silencing HCV RNA. Gene Therapy (2006) 13, 883-892.
Introduction
An estimated 170 million people worldwide are persistently infected with hepatitis C virus (HCV). 1 Although the initial infection is frequently asymptomatic, there are several subsequent clinical manifestations, including fibrosis of the liver, cirrhosis and hepatocellular carcinoma. Although combination therapy with interferon (IFN)-a and ribavirin has markedly improved the clinical outcome, less than half of the patients with chronic hepatitis C can be expected to respond favorably to currently available agents. 2 Therefore, developing a new therapy for chronic HCV is a major public health objective.
The genome of HCV, a member of Flaviviridae family, is encoded in an approximately 9.6-kb single-stranded RNA with positive polarity that includes a 5 0 -untranslated region (UTR) 3 and a 3 0 -UTR containing a 3 0 X terminal sequence. 4 Hepatitis C virus displays a high rate of mutation and is classified into distinct genotypes (1) (2) (3) (4) (5) (6) and subtypes, whose distribution varies both geographically and between risk groups. 5 Furthermore, several distinct but closely related HCV sequences coexist within each infected individual. These are referred to as quasispecies and reflect the high replication rate of the virus and the lack of a proofreading activity of the RNAdependent RNA polymerase. 6, 7 Gene targeting with functional nucleic acids is commonly used to determine gene function and has potential as a treatment for viral diseases. Although antisense RNA and ribozyme technologies are successful in some situations, they have been difficult to apply universally and are less effective in vivo. 8 A possible alternative, sequence-specific post-transcriptional gene silencing by double-stranded RNA (dsRNA), also known as RNA interference (RNAi), has been found in plants, Caenorhabditis elegans and mammalian cells. 9, 10 As RNAi with small interfering RNA (siRNA) can inhibit the replication of several viruses, including human immunodeficiency virus type 1 (HIV-1) 11 and poliovirus, 12 it may be a powerful new antiviral therapy. Recently, it has been demonstrated that replication of HCV RNA is also receptive to RNAi machinery, [13] [14] [15] [16] [17] [18] but it has been difficult to design highly effective siRNAs against HCV because of the exquisite sequence specificity of the siRNAs coupled with the variation in HCV genotypes and the enormous diversity of HCV sequences between and within infected individuals.
In this report, we show that dicer-generated siRNAs from long dsRNA can silence the replication of HCV RNA of different genotypes. Furthermore, we employed the modified long hairpin-RNA (hRNA) expression system to inhibit HCV replication and to avoid triggering the IFN response, which is normally caused by dsRNA. We demonstrated that intracellular-diced dsRNA can be used in mammalian cells to silence HCV RNA and, therefore, that long dsRNA-mediated RNAi could be useful as a therapeutic agent for natural viral infection by HCV.
Results
Synthetic small interfering RNA inhibits hepatitis C virus replication in HuH-7 cells containing replicating hepatitis C virus RNA As siRNA-mediated RNAi is strictly sequence specific, an siRNA targeting site was selected in regions conserved among the various HCV genotypes. Of the HCV genome sequences, the 5 0 -UTR and the 3 0 X region are the most highly conserved. 19 Therefore, we selected six sites in the 5 0 -UTR or core coding regions (A-F) and three sites in the 3 0 X regions (G-I) (see Materials and methods). HuH-7 cells carrying the HCV replicon were established as described. 20 We also modified the replicon RNA derived from the HCV genotype 1b clone (GenBank accession number AY045702) by substituting the neo r gene with the firefly luciferase gene fused to foot-andmouth disease virus (FMDV) 2A and the neo r gene (named the R6FLR-N replicon). This modification enables the sensitive and precise quantification of HCV replication levels using a luciferase assay.
To examine the ability of siRNAs to inhibit HCV replication, the nine synthetic siRNAs were transfected into R6FLR-N replicon cells (Figure 1a, left) . Of the siRNAs, siE (nucleotides (nt) 325-344) was the most effective and it dose-dependently inhibited HCV replication (Figure 1a, right) . Moreover, continuous transfection with siE but not the negative control p53m siRNA caused a gradual decrease in the HCV replicon titer up to the 23rd day (Figure 1b) . Using Northern blot analysis, we confirmed that the effects of siRNAs on the luciferase activity are associated with siRNA-directed degradation of the HCV replicon RNA (data not shown). These results indicated that siE was the most potent siRNA for inhibiting HCV replication of the selected siRNA sites.
Effect of ex-vivo dicer-generated small interfering RNAs from long double-stranded RNA We found that shifting the siRNAs 5 0 or 3 0 from the siE target position reduced the efficacy of siRNA-mediated RNAi (Figure 2a) . Therefore, to overcome site specificity of the selected siRNAs, we prepared ex-vivo recombinant human dicer (rhDicer)-generated siRNAs (d-siRNAs) from long dsRNAs (Figure 2b) . 21 R6FLR-N replicon cells were transfected with d-siRNAs targeting the HCV genome or p53 mRNA (negative control). Luciferase reporter assays indicated that d-siRNAs generated from the 5 0 -UTR of HCR6 sequences (D5-357, D5-197, and D5-50) silenced the HCV RNA more efficiently than siE. In contrast, the d-siRNAs generated from the 3 0 -UTR of the HCR6 sequences were less effective than siE. These results indicated that d-siRNAs generated from 5 0 -UTR containing the siE sequences, especially those generated from 197-bp dsRNAs, were more effective than the synthetic siE.
Dicer-generated siRNAs generated from 197-bp double-stranded RNA overcome hepatitis C virus genotype variation Genotype 1b-derived d-siRNAs generated from the conserved sequence motifs within the NS5B sequence do not block the replication of HCV genotypes 1a and 2a.
14 To examine whether our selected d-siRNAs can overcome HCV genotype variation, we transfected genotype 2a-specific d-siRNAs into R6FLR-N replicon cells, which harbor the genotype 1b replicon. As shown in Figures 3a and b , the genotype 2a-derived d-siRNAs generated from 197-bp dsRNA efficiently inhibited genotype 1b replication, even though genotypes 2a and 1b differ by 15 bases within the 197-bp dsRNA sequences (sequence homology ¼ 92%). In contrast, genotype 2a-derived siE, which harbors a single mutation at position 18 of the sense strand (sequence homology ¼ 95%), showed a weak silencing activity against genotype 1b. These results demonstrated that d-siRNAs generated from the 197-bp dsRNA were highly effective for RNAi and could overcome HCV genotype variation.
Long double-stranded RNA transfection into HuH-7 replicon cells induces target-specific silencing Dicer is a large multi-domain protein present in all eukaryotes. 22 Recently, Kim et al. 23 reported that syn- thetic RNA duplexes 25-30 nt in length are substrates of the dicer endonuclease, directly linking the production of siRNAs to incorporation in the RNA-induced silencing complex. We also expected that intracellular dsRNA duplexes longer than 50 nt would be recognized by dicer and thus induce RNAi. Therefore, we directly transfected long dsRNA into R6CE2-N replicon cells, which harbor the core to NS2 portion of the HCV genome ( Figure 2b ). The same amount of dsRNA was transfected into replicon cells, and the replicon copy number was determined by quantitative real-time detection (RTD)-polymerase chain reaction (PCR). 24 We found that, except for the 817-bp dsRNA, the long dsRNAs targeting sites in the HCV genome reduced the HCV RNA copy number. In contrast, an unrelated dsRNA targeting a site in endogenous p53 mRNA had no effect (Figure 4a) . A luciferase assay in R6FLR-N replicon cells showed similar results for HCV-specific silencing (data not shown). On the other hand, immunoblot analysis with antibodies against p53 showed that p53-specific long dsRNA suppressed the level of p53 protein, whereas HCV-specific dsRNA had no effect on p53 expression ( Figure 4b ). These results indicated that in HuH-7 replicon cells, direct transfection of long dsRNA can specifically produce RNAi against HCV and reduce endogenous p53 expression.
Effect of long double-stranded RNA on the intracellular interferon response and cell death in HepG2 cells
In mammalian cells, Toll-like receptor (TLR) 3 25, 26 recognizes dsRNA duplexes longer than 30 nt. This binding induces a type I IFN response, resulting in cell Long dsRNA-mediated RNAi for HCV T Watanabe et al death by apoptosis. 27 To examine the type I IFN response caused by direct transfection of dsRNA, we measured the intracellular IFN-b mRNA copy number and assessed cell viability. The IFN-b mRNA levels of R6FLR-N replicon cells (HuH-7 replicon cells) and the numbers of viable cells did not change following transfection with long dsRNAs or with the RNA duplex poly(rI):poly(rC) (Figures 4c and d) . These results show that the dsRNA did not induce intracellular IFN-b mRNA or enhance apoptosis in HuH-7 replicon cells.
HuH-7 replicon cell lines are used as models for HCV replication and do not respond to the IFN signals. 28 We therefore investigated the effect of dsRNAs on the IFN-b response in another cell type. As an alternative model, we used HepG2 cells stably expressing the full genome HCV RNA (Rz-HepM6 cells). 29 Transfection with poly (rI):poly(rC) or long dsRNAs induced an IFN-b mRNA level of 10 3 -10 5 copies per mg total RNA, whereas siRNA-20, a 20-nt duplex, induced only 10 copies per mg total RNA (Figure 4c) . Furthermore, the number of viable Rz-HepM6 cells was reduced by transfection with long dsRNAs, but not with siRNA-20 ( Figure 4d ). These results indicated that direct transfection with dsRNA duplex longer than 50 nt induces IFN-b mRNA and causes cytotoxicity in Rz-HepM6 cells, but not in HuH-7 replicon cells. Therefore, to observe the knockdown efficiency of long-dsRNA against the HCV replicating model and the IFN response induced by long dsRNA, we tested the effects of RNAi in HuH-7 replicon, Rz-HepM6 and HepG2 cells.
U6 promoter-driven expression of long hairpin-RNA with mutations in the sense strand causes gene silencing without triggering an interferon response or cell death
We examined the ability of a stable hairpin-type siRNAexpression vector [30] [31] [32] to silence the HCV genome. Recently, U6 promoter-driven transcription of hRNA with mutations in the sense strand has been reported to be more effective for RNAi than hRNA containing nonmutated sense strands. 32 Therefore, we constructed vectors for U6 promoter-driven expression of hRNAs containing multiple mutations (mhRNA) and examined their ability to cause gene silencing. To confirm the RNAi effect, we transfected the long mhRNA-expression vectors into R6FLR-N replicon cells. The 50-and 197-bp mhRNA vectors against the HCV sequence reduced luciferase activity as effectively as the siE-20-bp mhRNA vector (Figure 5a ). Furthermore, in Rz-HepM6 cells, the 50-and 197-bp mhRNA vectors targeted to the HCV sequence specifically suppressed HCV core protein expression (Figure 5b ). To avoid the inhibition of IFN-b activation by HCV itself, 28 we next examined the IFN response in original HepG2 cells. In contrast to the direct transfection of dsRNAs targeted to the same sequences, the 50-and 197-bp mhRNA vectors did not induce the expression of IFN-b mRNA (Figure 5c ). Owing to palindrome structure-specific recombination in the mammalian gene, 33 it was not possible to construct stably transformed cells expressing hRNA vectors against the 
HCV sequence containing non-mutated sense strands longer than 50 bp. Using control vectors against the luciferase gene (U6-50c, U6-50m, U6-100c and U6-100m), we confirmed an intracellular IFN response. In RzHepM6 cells, all of the mhRNA vectors (HCVm-20 bp, U6-50m and U6-100m) had a reduced IFN response compared to the hRNA vectors containing non-mutated sense strands (HCVc-20 bp, U6-50c and U6-100c; Figure  5d ). Moreover, U6 promoter-driven expression of long mhRNAs against the HCV sequence was not cytotoxic (Figure 5e ). These results indicated that in IFN-responsive cells, U6 promoter-driven expression of modified long dsRNA, which be made by inserting multiple mutations in the sense strand of hRNA, can effectively and specifically silence HCV without triggering the IFN response or cell death.
Discussion
Previous studies have shown that HCV RNA can be suppressed by the RNAi machinery in replicon cells. [13] [14] [15] [16] [17] [18] We demonstrated that there are two significant limitations for the use of siRNA-mediated RNAi as a therapy for HCV: first, it is difficult to predict which target site will be most effective for siRNA; and, second, it is difficult to target the other HCV genotypes with multiple sequences. We further examined the ability of d-siRNAs and intracellular-diced long dsRNAs to overcome these problems and inhibit HCV replication in HCV replicon Long dsRNA-mediated RNAi for HCV T Watanabe et al cells. We found that ex-vivo dicer-generated siRNAs generated from the 5 0 -UTR sequences are more effective for silencing than the most potent synthetic siRNA, siE. Our results further demonstrated that 50-and 197-bp dsRNA regions of the HCV genome are potential target areas for RNAi. Although dsRNA duplexes targeting the 50-to 357-bp sites in the HCV genome efficiently cause target silencing, dsRNA duplexes targeting the 817-bp HCV genome are less effective for HCV replication. This suggests that the area of the HCV genome that can be targeted by the RNAi machinery is restricted because of the formation of a complex internal ribosome entry site structure. Recently, Kim et al. 23 showed that 27-mer duplexes that are substrates of cellular dicer have enhanced RNAi potency and efficacy in mammalian cells. Our results also suggest that siRNAs generated by dicer from dsRNA duplexes longer than 50 nt are available in their natural form and, therefore, can have enhanced efficacy for RNAi.
In HuH-7 HCV replicon cells, which lack a long dsRNA-induced IFN response, the long dsRNAs were effective at causing RNAi of the HCV genome or endogenous p53. Therefore, we further examined the effect of dsRNA on HepG2 cells, in which dsRNA causes production of IFN-b and activates downstream signaling, including 2 0 -5 0 -oligoadenylate synthetase and protein kinase R. 29 Although transfection with dsRNA duplexes longer than 50 nt induced IFN-b and caused cell death, U6 promoter-driven expression of long hRNAs containing multiple point mutations in the sense strand (i.e., near-complementary inverted repeats) efficiently inhibited HCV replication, but was not cytotoxic. Moreover, the intracellular IFN-b mRNA titer was equivalent to that induced by the control U6 vector. The precise mechanism is now under investigation, but it is clear that this system allows intracellular-diced long dsRNA to induce RNAi without activating the IFN response in mammalian cells.
The genotype 2a-derived d-siRNAs generated from the 197-bp dsRNA were able to efficiently inhibit HCV genotype 1b replication. Thus, siRNAs generated from long dsRNA can cause silencing of heterogeneous viruses and should be able to overcome siRNA escape mutations. Long-term HIV-1 replication assays 34 revealed that, after 3-6 weeks of culture, siRNA-mediated RNAi-resistant viruses containing nucleotide substitutions or deletions in the target sequence arise. Wilson et al. 35 reported that HCV replicons escaped RNAi induced by subsequent treatment with the same siRNA directed against the NS5B cording region. In contrast, we also examined the long-term efficiency of long dsRNAmediated RNAi using HCV replicon cells. When examined over 5 weeks with continuous transfection of 197-bp dsRNA, the HCV replicon RNA titer gradually decreased to a 100-fold reduction and never rebounded (data not shown). The degree of sequence conservation reflects the fact that the structural elements in the 5 0 -and 3 0 -terminal regions of the RNA are essential for viral replication. 36, 37 Therefore, long dsRNA-mediated RNAi targeting a site in the 5 0 -UTR can avoid the problem of escape virus generation because extensive alterations in a conserved region of the viral genome would be required.
In summary, our results show that dicer-generated siRNAs from long dsRNA are highly effective for RNAi of the HCV genome and overcome genotype variations. We also showed that U6 promoter-driven expression of modified long dsRNA avoids activation of the IFN response and the induction of cell death normally caused by dsRNA. This strategy should be useful for therapy against natural viral infection by HCV and other RNA viruses, such as HIV-1, that display a high rate of mutation.
Materials and methods

Small interfering RNAs
We synthesized T7 siRNAs using the Silencer siRNA Construction Kit (Ambion, Austin, TX, USA) according to the manufacturer's instructions. The sense sequences of siRNAs were as follows: The sense sequence of the p53 m siRNA, which contains two nucleotide mismatches in the target sequence, 38 was 5 0 -GACUCCAGUGAUAAUCUGCUU-3 0 (nucleotide mismatches underlined).
Long double-stranded RNAs
Long dsRNAs were prepared by in vitro transcription of PCR-amplified DNA templates. A modified T7 promoter sequence was added to the 5 0 -end of each PCR primer for amplification ( Table 1 ). The dsRNAs were produced from the purified DNA templates using an Ampliscribe T7 transcription kit (Epicenter Technologies, Madison, WI, USA). Single-stranded RNA was converted to dsRNA by allowing annealing the two strands. Purification of dsRNA was performed as described for dicergenerated siRNAs.
Dicer-generated small interfering RNAs
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Construction of U6 vectors
Plasmids containing a human U6 promoter were prepared as described previously. 30 
Construction of recombinant plasmids for expressing the hepatitis C virus replicon
The HCV genotype 1b replicon pRep-R6FLR-NRz was assembled and cloned from pRep-R6Rz and the 1bneo/ delS plasmid. 39 Replicon pRep-R6Rz was engineered from pHCR6-Rz 29 as described previously, 20 and replicon pRep-R6-NRz was engineered by replacing a NS3-NS5B fragment (nt 3420-7996; MfeI site) in pRep-R6Rz with a NS3-NS5B fragment (nt 3420-7996; MfeI site) from the 1bneo/delS plasmid. The final replicon, pRep-R6FLR- 
Cell culture and transfection
We maintained the human hepatoma cell line HuH-7 in complete Dulbecco's modified Eagle medium (DMEM; Invitrogen, Carlsbad, CA, USA). G418 was added to a final concentration of 500 mg/ml to cell lines carrying HCV replicons. 20 Replicon cells were transfected with synthetic siRNA using Trans IT TKO reagent (Mirus, Madison, WI, USA) or with modified siE, dicer-generated siRNAs, long dsRNA and DNA vector using Lipofectamine 2000 (Invitrogen) according to the manufacturer's protocol. Also, Rz-HepM6 cells 29 were transfected with various amounts of dsRNAs or DNA vector using Lipofectamine 2000.
Luciferase assays
The luciferase assay was performed using the SteadyGlo or Bright-Glo luciferase assay systems (Promega). Luciferase activities were quantified using a luminometer (Mithras LB940; Berthold Technologies, Wildbad, Germany).
Cell viability assay
To evaluate the cytotoxic effects of dsRNAs, cell viability was measured by metabolic conversion of 2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium, monosodium salt (WST-8) using a Cell Counting Kit-8 (Wako, Tokyo, Japan) according to the manufacturer's protocol. 
Immunoblot analysis
Immunoblot analysis was performed as described previously. 29 Anti-p53 (Novocastra Laboratories Ltd, Newcastle Upon Tyne, UK) and anti-b-actin (Santa Cruz Biotechnology, Santa Cruz, CA, USA) were used as the primary antibodies.
Real-time detection-polymerase chain reaction analysis
The HCV genome RNA and IFN-b mRNA were quantified using the ABI PRISM 7700 sequence detector (Applied Biosystems, Foster City, CA, USA) as described previously. 24, 29 Quantification of hepatitis C virus core protein Hepatitis C virus core protein was assessed in cell lysates using a fluorescent enzyme-linked immunosorbent assay. 40 
